Publications
297 results found
Agarwal R, Seckl MJ, Nelstrop A, et al., 1999, A phase II study of sequential carboplatin (C), paclitaxel (P) and topetecan (T) in patients with previously untreated advanced ovarian cancer, BRITISH JOURNAL OF CANCER, Vol: 80, Pages: 107-107, ISSN: 0007-0920
Pardo OE, Seckl MJ, 1999, Fibroblast growth factor 2 (FGF-2) potently stimulates early signalling events and growth of small cell lung cancer cells, BRITISH JOURNAL OF CANCER, Vol: 80, Pages: 87-87, ISSN: 0007-0920
Fisher RA, Paradinas FJ, Seckl MJ, et al., 1999, Molecular genetic diagnosis of trophoblastic tumours, BRITISH JOURNAL OF CANCER, Vol: 80, Pages: 83-83, ISSN: 0007-0920
Leonard DM, Macharia GJ, Glaser M, et al., 1999, Effects of tamoxifen or N-desmethyl-tamoxifen combined with radiotherapy on glioma cell growth., Publisher: CHURCHILL LIVINGSTONE, Pages: 34-34, ISSN: 0007-0920
Lo SK, Montgomery JN, Blagden S, et al., 1999, Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics, LANCET, Vol: 353, Pages: 2038-2039, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 5
Newlands ES, Foskett MA, Seckl MJ, et al., 1999, The management and outcome in patients presenting with twin/multiple pregnancies complicated by a complete hydatidiform mole (CHM) and patients presenting with partial hydatidiform mole (PHM), 7th Biennial Meeting of the International-Gynecologic-Cancer-Society, Publisher: MEDIMOND S R L, Pages: 43-47
Kanfer EJ, McGuigan D, Samson D, et al., 1998, High dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels, BRITISH JOURNAL OF CANCER, Vol: 78, Pages: 928-932, ISSN: 0007-0920
High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this is associated with significant toxicity. Sixty-three patients with malignancy were enrolled into this non-randomized sequential study. The majority (55/63, 87%) had received at least two prior regimens of chemotherapy, and seven patients had previously failed to mobilize following high-dose cyclophosphamide with G-CSF. Consecutive patient groups received etoposide at three dose levels [2.0 g m(-2) (n = 22), 1.8 g m(-2) (n = 20) and 1.6 g m(-2) (n = 21)] followed by daily G-CSF. Subsequent leukaphereses were assayed for CD34+ cell content, with a target total collection of 2.0 x 10(6) CD34+ cells kg(-1). Toxicity was assessed by the development of significant mucositis, the requirement for parenteral antibiotics or blood component support and rehospitalization incidence. Ten patients (16%) had less than the minimum target yield collected. Median collections in the three groups were 4.7 (2 g m(-2)), 5.7 (1.8 g m(-2)) and 6.5 (1.6 g m(-2)) x 10(6) CD34+ cells kg(-1). Five of the seven patients who had previously failed cyclophosphamide mobilization achieved more than the target yield. Rehospitalization incidence was significantly lower in patients receiving 1.6 g m(-2) etoposide than in those receiving 2.0 g m(-2) (P = 0.03). These data suggest that high-dose etoposide with G-CSF is an efficient mobilization regimen in the majority of heavily pretreated patients, including those who have previously failed on high-dose cyclophosphamide with G-CSF. An etoposide dose of 1.6 g m(-2) appears to be as effective as higher doses but less toxic.
Woolas RP, Bower M, Newlands ES, et al., 1998, Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome, BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, Vol: 105, Pages: 1032-1035, ISSN: 0306-5456
- Author Web Link
- Cite
- Citations: 60
Savage P, Roddie M, Seckl MJ, 1998, A 28-year-old woman with a pulmonary embolus, LANCET, Vol: 352, Pages: 30-30, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 14
Seckl MJ, Rozengurt E, 1998, Substance P analogues act as broad-spectrum neuropeptide antagonists, 2nd Symposium on Design, Synthesis and Structure of Peptidomimetics, Publisher: KLUWER ACADEMIC PUBL, Pages: 199-204, ISSN: 0929-5666
- Author Web Link
- Cite
- Citations: 1
Stern SCM, Giles C, Olavarria E, et al., 1998, Autologous peripheral blood progenitor cell transplantation in relapsed germ cell tumours; A novel conditioning regimen containing paclitaxel is well tolerated and causes little regimen-related toxicity., BONE MARROW TRANSPLANTATION, Vol: 21, Pages: S231-S231, ISSN: 0268-3369
Newlands ES, Bower M, Holden L, et al., 1998, Management of resistant gestational trophoblastic tumors, JOURNAL OF REPRODUCTIVE MEDICINE, Vol: 43, Pages: 111-118, ISSN: 0024-7758
- Author Web Link
- Cite
- Citations: 34
Christmas TJ, Doherty AP, Rustin GJS, et al., 1998, Excision of residual masses of metastatic germ cell tumours after chemotherapy: the role of extraperitoneal surgical approaches, BRITISH JOURNAL OF UROLOGY, Vol: 81, Pages: 301-308, ISSN: 0007-1331
- Author Web Link
- Cite
- Citations: 14
Seckl MJ, Rozengurt E, 1998, Neuropeptides, signal transduction and small cell lung cancer, Workshop on Prevention and Early Detection of Lung Cancer, Publisher: BIRKHAUSER VERLAG AG, Pages: 129-142
- Author Web Link
- Cite
- Citations: 4
Seckl MJ, Newlands ES, 1997, Treatment of gestational trophoblastic disease., Gen Diagn Pathol, Vol: 143, Pages: 159-171, ISSN: 0947-823X
Gestational trophoblastic disease (GTD) forms a spectrum of illness from the borderline malignancy of hydatidiform mole to the highly aggressive behaviour of choriocarcinoma. In the past, many women have died from this group of disorders. However, during the last 45 years highly effective chemotherapy regimens have been developed which can be appropriately tailored to the individual patient's risk of becoming resistant to the treatment. As a result, the management of GTD is one of the modern success stories in oncology. Today, with an integrated approach to management few women die from their trophoblastic tumours.
Christmas TJ, Doherty AP, Rustin GJS, et al., 1997, Primary retroperitoneal germ cell tumours: Excision via a thoracoabdominal extraperitoneal approach, BRITISH JOURNAL OF SURGERY, Vol: 84, Pages: 1022-1025, ISSN: 0007-1323
- Author Web Link
- Cite
- Citations: 2
Seckl MJ, Higgins T, Widmer F, et al., 1997, [D-Arg(1),D-Trp(5,7,9),Leu(11)]Substance P: A novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells, CANCER RESEARCH, Vol: 57, Pages: 51-54, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 79
Seckl MJ, Higgins T, Rozengurt E, 1996, [D-Arg(1),D-Trp(5,7,9),Leu(11)]substance P coordinately and reversibly inhibits bombesin- and vasopressin-induced signal transduction pathways in Swiss 3T3 cells, JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 271, Pages: 29453-29460, ISSN: 0021-9258
- Author Web Link
- Cite
- Citations: 22
Seckl MJ, Rozengurt E, 1996, Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro, EUROPEAN JOURNAL OF CANCER, Vol: 32A, Pages: 342-345, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 4
SECKL MJ, NEWMAN RH, FREEMONT PS, et al., 1995, SUBSTANCE P-RELATED ANTAGONISTS INHIBIT VASOPRESSIN AND BOMBESIN BUT NOT 5'-3-O-(THIO)TRIPHOSPHATE-STIMULATED INOSITOL PHOSPHATE PRODUCTION IN SWISS 3T3 CELLS, JOURNAL OF CELLULAR PHYSIOLOGY, Vol: 163, Pages: 87-95, ISSN: 0021-9541
- Author Web Link
- Cite
- Citations: 17
SECKL MJ, MORII N, NARUMIYA S, et al., 1995, GUANOSINE 5'-3-O-(THIO)TRIPHOSPHATE STIMULATES TYROSINE PHOSPHORYLATION OF P125(FAK) AND PAXILLIN IN PERMEABILIZED SWISS 3T3 CELLS - ROLE OF P21(RHO), JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 270, Pages: 6984-6990, ISSN: 0021-9258
- Author Web Link
- Cite
- Citations: 71
SECKL MJ, SEUFFERLEIN T, ROZENGURT E, 1994, LYSOPHOSPHATIDIC ACID-DEPLETED SERUM, HEPATOCYTE GROWTH-FACTOR AND STEM-CELL GROWTH-FACTOR STIMULATE COLONY GROWTH OF SMALL-CELL LUNG-CANCER CELLS THROUGH A CALCIUM-INDEPENDENT PATHWAY, CANCER RESEARCH, Vol: 54, Pages: 6143-6147, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 19
SECKL M, ROZENGURT E, 1993, TYRPHOSTIN INHIBITS BOMBESIN STIMULATION OF TYROSINE PHOSPHORYLATION, C-FOS EXPRESSION, AND DNA-SYNTHESIS IN SWISS 3T3 CELLS, JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 268, Pages: 9548-9554, ISSN: 0021-9258
- Author Web Link
- Cite
- Citations: 51
SECKL MJ, RUSTIN GJS, COOMBES RC, 1992, CA-125 IS NOT A USEFUL MARKER IN METASTATIC BREAST-CANCER, BRITISH JOURNAL OF CANCER, Vol: 66, Pages: 875-876, ISSN: 0007-0920
SECKL MJ, RUSTIN GJS, NEWLANDS ES, et al., 1991, PULMONARY-EMBOLISM, PULMONARY-HYPERTENSION, AND CHORIOCARCINOMA, LANCET, Vol: 338, Pages: 1313-1315, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 25
SECKL MJ, RUSTIN GJS, BAGSHAWE KD, 1990, FREQUENCY OF SERUM TUMOR-MARKER MONITORING IN PATIENTS WITH NONSEMINOTAMOUS GERM-CELL TUMORS, BRITISH JOURNAL OF CANCER, Vol: 61, Pages: 916-918, ISSN: 0007-0920
- Author Web Link
- Cite
- Citations: 12
SECKL MJ, RUSTIN GJS, BAGSHAWE KD, 1989, FREQUENCY OF SERUM TUMOR-MARKER MONITORING IN PATIENTS WITH NON-SEMINOMATOUS GERM-CELL TUMORS, BRITISH JOURNAL OF CANCER, Vol: 59, Pages: 822-823, ISSN: 0007-0920
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.